PD-1+ T cells broadly impact multiple clinically validated drivers of RA pathogenesis

>80% of T cells in RA synovium are PD-1+

• Similar findings are observed in treatment naïve and biologic experienced patients

Adapted from Aletaha and Smolen, JAMA, 2018

Rosnilimab Phase 2b data through six month in RA

Rosnilimab, a best-in-class depleter and agonist targeting PD-1+ T cells, is well-positioned for the ~$20 billion U.S. RA market which hasn’t had a new mechanism approved since 2012

For specific data, see press release and IR presentation.

LDA response rates and durability for rosnilimab are differentiated from Lilly’s peresolimab

1. Non-responder imputated (NRI) analysis on intent-to-treat (ITT) of all 318 rosnilimab patients randomized; 2. At Week 28, 53% (100mg Q4W), 54% (400mg Q4W), and 63% (600mg Q2W) rosnilimab patients were in CDAI LDA (57% pooled); 3. Off-drug follow-up period ongoing; 4. Tuttle et. al, NEJM, May 2023, Supplemental Appendix, At Week 28, 36% (300mg Q4W) and 37% (700mg Q4W) peresolimab patients were in CDAI LDA

To learn more about our clinical trial for Rheumatoid Arthritis please click here.